Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • NPPA directs 3 pharma...

    NPPA directs 3 pharma cos to maintain stock of atleast 2.2 crore tablets of FDC Lopinavir and Ritoavir

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-29T13:19:29+05:30  |  Updated On 29 March 2020 1:19 PM IST
    NPPA directs 3 pharma cos to maintain stock of atleast 2.2 crore tablets of FDC Lopinavir and Ritoavir

    New Delhi: The National Pharmaceuticals Pricing Authority (NPPA), Department of Pharmaceuticals directed 3 major manufacturers of the HIV Combo drug Lopinavir & Ritonavir to maintain the adequate stock of Lopinavir & Ritonavir to fight against the corona pandemic. The combination drug has shown efficacy in treatement of coronavirus in certain cases

    The order directs three manufacturers of the said drug, namely Mylan, Cipla and Aurobindo to make sure that stock of atleast 2.2 crore tablets are maintained at any point in time

    " In pursuance to directions given by Department of Pharmaceuticals, the drug manufacturers of FDC namely `Lopinavir & Ritonavir' (200 Mg+50 Mg.) are hereby directed, in the public interest, in order to deal with the situation arising out of COVID-19, to maintain the stock level of said FDC at least 2.20 Crore tablets at any point of time and also to ensure sufficient availability of the said FDC till further orders. The drug manufacturers will maintain stock of said FDC as indicated against the concerned company's name below," the order added

    The order whichwas made by Manjesh Porwal, Dy. Director(Enf.) specifically asked the three manufacturers to maintain atleast the following stock

    1) Mylan Laboratories Ltd. (140 Lakhs Tablets),

    2) Aurobindo Pharma Ltd. (40 Lakhs Tablets),

    3) Cipla Ltd. (40 Lakhs Tablets).

    The copy for the same has been submitted to PSO to Secretary (Pharma) (w.r.t. Directions issued dated 19th March 2020), Sr. PPS to Secretary (Health), Director General, ICMR, Sr. PPS to Chairman, NPPA, PPS to JS (Policy), Deptt. of Pharmaceuticals

    The Drug Controller General of India has approved "restricted use" of the combination of medications lopinavir and ritonavir which are second-line HIV drugs, for treating those affected by novel coronavirus after the Indian Council of Medical Research (ICMR) sought an emergency approval for the same.

    Read Also: SMS Hospital Gives Anti-HIV Drugs To Coronavirus-Affected Elderly Italian Couple

    For full details click on the following link:

    https://business.medicaldialogues.in/pdf_upload/pdf_upload-125985.pdf



    fdcnppanational-pharmaceuticals-pricing-authoritylopinavirritonavirciplamylanaurobindo pharma

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok